secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2022-04-05T23:59:59+00:00
Accession:  0001213900-22-018143
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer effective April 4, 2022
--------------------------------------------------------------------------------

- Dr. Min will lead global clinical development and regulatory strategy; focus on advancing Lomecel-B into pivotal trials and approval.
- Compensation: base salary $350k, performance bonus 30%, $60k signing bonus (half RSUs, half options), plus 150k RSUs and 50k stock options vesting over 4 years.
- Dr. Min brings over a decade of pharma/biotech experience including roles at Merck, Cerevel, BlueRock, and Enterin; board-certified neurologist.
- Annual shareholder meeting set for June 24, 2022; proposal deadlines: Rule 14a-8 proposals due May 6, other business notice due June 17.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390022018143/0001213900-22-018143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390022018143/ea158049-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-018143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer